| Literature DB >> 30675163 |
Seesai Yeesoonsang1, Edward McNeil1, Shama Virani1, Surichai Bilheem1, Chakrarat Pittayawonganon2, Chuleeporn Jiraphongsa3, Hutcha Sriplung1.
Abstract
BACKGROUND: The incidence of liver and bile duct cancer continues to rise, especially in Thailand. We aimed to project the trends in incidence of this rare but lethal cancer in southern Thailand in order to determine its future disease burden.Entities:
Year: 2018 PMID: 30675163 PMCID: PMC6323434 DOI: 10.1155/2018/8267059
Source DB: PubMed Journal: J Cancer Epidemiol ISSN: 1687-8558
Liver and bile duct cancer cases by histological type and sex before and after imputation.
| Histologic subtype | All (n=2,676) | Males (n=1,947) | Females (n=729) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before | % | After | % | Before | % | After | % | Before | % | After | % | |
| HCC | 409 | 15.4 | 1,188 | 44.4 | 329 | 16.9 | 1004 | 51.6 | 80 | 11.0 | 184 | 25.2 |
| CCA | 358 | 13.4 | 1,020 | 38.1 | 206 | 10.6 | 657 | 33.7 | 152 | 20.8 | 363 | 49.8 |
| Other† | 165 | 6..1 | 468 | 17.5 | 89 | 4.5 | 286 | 14.7 | 76 | 10.4 | 182 | 25.0 |
| Unknown‡ | 1,455 | 54.3 | - | - | 1,152 | 59.1 | - | - | 303 | 41.6 | - | - |
| Unknown¶ | 289 | 10.8 | - | - | 171 | 8.8 | - | - | 118 | 16.2 | - | - |
HCC: hepatocellular carcinoma, CCA: cholangiocarcinoma, †liver and bile duct cancer with unspecified histology, ‡liver cancer with unknown histology, and ¶malignant neoplasms of the abdomen (C76.2) and unknown primary site (C80.9).
Number and percentage of liver and bile duct cancers by gender and histologic subtype (n=2,676).
| Variable | Males | Females | ||||||
|---|---|---|---|---|---|---|---|---|
| HCC (n=1,004) | CCA (n=657) | HCC (n=184) | CCA (n=363) | |||||
| Number | % | Number | % | Number | % | Number | % | |
| Age group (years) | ||||||||
| <40 | 91 | 9.1 | 43 | 6.5 | 17 | 9.2 | 34 | 9.4 |
| 40-49 | 176 | 17.5 | 105 | 16.0 | 25 | 13.6 | 35 | 9.6 |
| 50-59 | 298 | 29.7 | 158 | 24.0 | 39 | 21.2 | 51 | 14.0 |
| 60-69 | 280 | 27.9 | 156 | 23.7 | 53 | 28.8 | 87 | 24.0 |
| 70-79 | 141 | 14.0 | 125 | 19.0 | 41 | 22.3 | 91 | 25.1 |
| ≥80 | 18 | 1.8 | 70 | 10.7 | 9 | 4.9 | 65 | 17.9 |
| Period of diagnosis | ||||||||
| 1989-1993 | 122 | 12.2 | 45 | 6.8 | 25 | 13.6 | 30 | 8.3 |
| 1994-1998 | 143 | 14.2 | 64 | 9.7 | 18 | 9.8 | 33 | 9.1 |
| 1999-2003 | 158 | 15.7 | 106 | 16.1 | 36 | 19.6 | 58 | 16.0 |
| 2004-2008 | 292 | 29.1 | 204 | 31.1 | 44 | 23.9 | 104 | 28.7 |
| 2009-2013 | 289 | 28.8 | 238 | 36.2 | 61 | 33.2 | 138 | 38.0 |
HCC: hepatocellular carcinoma. CCA: cholangiocarcinoma.
Akaike information criterion values for the age-period, age-cohort, and age-period-cohort models against the age-drift model.‡
| Model | Hepatocellular carcinoma | Cholangiocarcinoma | ||
|---|---|---|---|---|
| Male | Female | Male | Female | |
| Age-period | 1520.5† | 1522.4 | 1527.6 | 1519.5 |
| Age-cohort | 1520.6 | 1522.3† | 1527.7 | 1519.5 |
| Age-period-cohort | 1521.0 | 1524.4 | 1523.8† | 1517.3† |
†The best fitting model based on the Akaike information criterion.
‡Relative values that weight the goodness-of-fit of the model to empirical data.
Figure 1Age-period-cohort (APC) trend analysis for hepatocellular (HCC) and cholangiocarcinoma (CCA) cancers by gender; (a) CCA-male, (b) CCA-female, (c) HCC-male, and (d) HCC-female. For each group, the models with the lowest AIC value presented in Table 3 are drawn over the ones with higher AIC value. The thin lines above and below the three effects represent their 95% confidence interval.
Figure 2Age-standardized incidence rates of liver and bile duct cancers in Songkhla by the major histologic subtypes; hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), using three projection models; joinpoint regression, age-period-cohort, and Nordpred, by gender in 1989-2013 and projection until 2030. PY: person-years.
Figure 3Estimated number of liver and bile duct cancers in Songkhla by the major histologic subtypes; hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), using three projection models; joinpoint analysis, age-period-cohort, and Nordpred by sex in 1989-2013 and projection until 2030.